Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 13/20 | 0.40 |
| ▸ | DPP4 | P27487 | 4/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899095 | 1.00 | PTGES (0.40) | PTGESDPP4DPP7KCNH2HPGDS | |
| SCHEMBL9944795 | 0.89 | TAS1R3 (0.40) | DPP4DPP7KCNH2 | |
| SCHEMBL9899449 | 0.85 | PTGES (0.39) | PTGESLIPG | |
| SCHEMBL9899446 | 0.85 | PTGES (0.39) | PTGESLIPG | |
| SCHEMBL9946795 | 0.81 | PTGES (0.46) | PTGESDPP4DPP7 | |
| SCHEMBL9946743 | 0.81 | PTGES (0.46) | PTGESDPP4DPP7 | |
| SCHEMBL14234258 | 0.79 | PTGES (0.42) | PTGESDPP4DPP7HPGDS | |
| SCHEMBL9942024 | 0.79 | PTGES (0.42) | PTGESDPP4DPP7HPGDS | |
| SCHEMBL9897664 | 0.78 | PTGES (0.40) | PTGES | |
| SCHEMBL9897667 | 0.78 | PTGES (0.40) | PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674113-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120149676-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012076673-A1 | 6-AMINO-2-PHENYLAMINO-1H-BENZIMIDAZOLE-5-CARBOXAMIDE- DERIVATIVES AND THEIR USE AS MICROSOMAL PROSTAGLANDIN E2 SYNTHASE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149676-A1 | NOVEL COMPOUNDS | PTGS1, PTGER1, PTGES | PTGES 3/4885DPP4 2717/4885DPP7 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.